首页> 外文OA文献 >Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)

【2h】

Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)

机译：试点研究评估高剂量ranibizumab 2.0mg在持续/复发性黄斑液患者患者的新血管年龄相关性黄斑运动中的作用<30天后玻璃体抗VEGF治疗（最后一项研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A T Fung; N Kumar; S K Vance; J S Slakter; J M Klancnik; R S Spaide; K B Freund;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [J] . FungA.T., KumarN., VanceS.K., Eye . 2012,第9期

机译：在玻璃体内注射抗VEGF治疗后持续/复发性黄斑积液<30天的患者中评估大剂量rAnibizumab 2.0 mg在管理新生血管性年龄相关性黄斑变性中的作用的试验研究（LAST研究）
2. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration [J] . Patrick D Williams, David Callanan, Wayne Solley, Clinical ophthalmology . 2012,第4期

机译：前瞻性先导研究比较玻璃体内雷珠单抗和半定量光动力疗法与雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的疗效
3. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. [J] . Sivaprasad S, Patra S, DaCosta J, Ophthalmologica: International Journal of Ophthalmology=Journal International d'Ophtalmologie . 2011,第4期

机译：减少通量光动力疗法，玻璃体内兰尼单抗，玻璃体内地塞米松和口服米诺环素联合治疗新血管性年龄相关性黄斑变性的初步研究。
4. Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration [C] . Leilei Zhang, Jeff Xu, Jiwei Huang, Conference on ophthalmic technologies . 2010

机译：贝伐单抗（Avastin）缀合的微泡用于抗VEGF治疗新生血管性年龄相关性黄斑变性
5. Characterizing response patterns to ranibizumab therapy in patients with wet age-related macular degeneration: A latent class growth analysis [D] . Sun, Diana 2015

机译：潮湿年龄相关性黄斑变性患者的ranibizumab治疗的表征反应模式：潜在的增长分析
6. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [O] . A T Fung, N Kumar, S K Vance, 2012

机译：评价玻璃体腔内抗VEGF治疗后持续/复发黄斑积液30天的患者中大剂量rAnibizumab2.0μmg在新生血管性黄斑变性管理中的作用的初步研究（LAST研究）
7. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study [O] . Jennifer J. Arnold, Caroline M. Markey, Nicol P. Kurstjens, 2016

机译：视网膜下液在确定新生血管性年龄相关性黄斑变性患者治疗结果中的作用-雷珠单抗的IV期随机临床试验：FLUID研究

Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)

著录项

相似文献

相关主题

期刊订阅